Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.


Journal

Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395

Informations de publication

Date de publication:
2020
Historique:
received: 07 10 2019
accepted: 19 11 2019
entrez: 28 2 2020
pubmed: 28 2 2020
medline: 15 4 2021
Statut: epublish

Résumé

CDK4/cyclin D kinase constitutes an attractive pharmacological target for development of anticancer therapeutics, in particular in

Identifiants

pubmed: 32104498
doi: 10.7150/thno.40971
pii: thnov10p2008
pmc: PMC7019173
doi:

Substances chimiques

Aminopyridines 0
Benzimidazoles 0
Cyclin D 0
KRAS protein, human 0
Peptides 0
abemaciclib 60UAB198HK
CDK4 protein, human EC 2.7.11.22
Cyclin-Dependent Kinase 4 EC 2.7.11.22
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2008-2028

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

J Am Chem Soc. 2007 Mar 7;129(9):2456-7
pubmed: 17284038
Nature. 2009 Nov 12;462(7270):182-8
pubmed: 19907488
JAMA Dermatol. 2013 Dec;149(12):1403-6
pubmed: 24108467
Lung Cancer. 2007 Jan;55(1):1-14
pubmed: 17070615
Molecules. 2018 Apr 19;23(4):
pubmed: 29671834
Cancer Lett. 2013 Jul 1;334(2):188-95
pubmed: 23200675
Clin Lung Cancer. 2016 Jan;17(1):80-4
pubmed: 26432508
J Pathol. 2011 Sep;225(1):83-95
pubmed: 21598249
Cancer Cell. 2010 Jul 13;18(1):63-73
pubmed: 20609353
Nat Rev Cancer. 2009 Mar;9(3):153-66
pubmed: 19238148
Cancers (Basel). 2015 Jan 23;7(1):179-237
pubmed: 25625291
Clin Cancer Res. 2019 Jan 1;25(1):6-8
pubmed: 30115629
Nature. 1995 Jul 27;376(6538):313-20
pubmed: 7630397
Nanomedicine. 2016 May;12(4):921-932
pubmed: 26724540
Clin Breast Cancer. 2016 Feb;16(1):8-17
pubmed: 26303211
Drug Discov Today. 2016 Jan;21(1):5-10
pubmed: 26210956
J Natl Cancer Inst. 2012 Mar 21;104(6):476-87
pubmed: 22302033
Nat Rev Drug Discov. 2009 Feb;8(2):111-28
pubmed: 19180105
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
Biosens Bioelectron. 2016 Nov 15;85:371-380
pubmed: 27203461
Nat Rev Drug Discov. 2009 Jul;8(7):547-66
pubmed: 19568282
Chembiochem. 2016 Apr 15;17(8):737-44
pubmed: 26946188
Cancer Discov. 2016 Jul;6(7):740-53
pubmed: 27217383
Curr Med Chem. 2011;18(19):2854-66
pubmed: 21651493
Chem Soc Rev. 2009 Dec;38(12):3289-300
pubmed: 20449049
J Biomed Opt. 2008 Jan-Feb;13(1):011008
pubmed: 18315357
Invest New Drugs. 2014 Oct;32(5):825-37
pubmed: 24919854
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W480-6
pubmed: 20511591
J Biol Chem. 2005 Apr 8;280(14):13793-800
pubmed: 15649889
Curr Opin Cell Biol. 2013 Dec;25(6):772-9
pubmed: 24011867
Science. 2004 Sep 3;305(5689):1466-70
pubmed: 15353804
Nat Cell Biol. 2009 Nov;11(11):1275-6
pubmed: 19884882
Lung Cancer. 2013 Oct;82(1):69-75
pubmed: 23927885
Clin Cancer Res. 2015 Jul 1;21(13):2905-10
pubmed: 25941111
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4166-70
pubmed: 19237565
Methods Enzymol. 2012;503:3-33
pubmed: 22230563
Cancer Res. 2016 Apr 15;76(8):2301-13
pubmed: 27020857
J Mol Biol. 2008 May 2;378(3):565-80
pubmed: 18374356
J Med Chem. 2014 Aug 14;57(15):6275-88
pubmed: 24601557
Int J Cancer. 2004 Jul 1;110(4):532-41
pubmed: 15122585
J Control Release. 2014 Dec 28;196:344-54
pubmed: 25451545
Expert Opin Investig Drugs. 2013 Jul;22(7):895-906
pubmed: 23735075
Mol Cell. 2006 Oct 20;24(2):199-210
pubmed: 17052454
Curr Opin Genet Dev. 2007 Feb;17(1):60-5
pubmed: 17208431
Front Oncol. 2014 Jul 23;4:190
pubmed: 25101246
Small. 2015 Jan 14;11(2):215-21
pubmed: 25201285
Methods Enzymol. 2008;446:369-86
pubmed: 18603134
Clin Cancer Res. 2014 Jul 1;20(13):3379-83
pubmed: 24795392
Oncotarget. 2018 Aug 3;9(60):31572-31589
pubmed: 30167080
Nat Rev Cancer. 2011 Jul 07;11(8):558-72
pubmed: 21734724
Nat Rev Drug Discov. 2016 Aug;15(8):533-50
pubmed: 27050677
Angew Chem Int Ed Engl. 1998 Dec 17;37(23):3281-3284
pubmed: 29711420
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Nat Chem. 2013 Mar;5(3):161-73
pubmed: 23422557
Chembiochem. 2019 Feb 15;20(4):605-613
pubmed: 30548750
J Biol Chem. 2017 Jun 16;292(24):10131-10141
pubmed: 28446612
J Biol Chem. 2002 Jun 28;277(26):23847-53
pubmed: 11959850
Trends Biochem Sci. 2005 Nov;30(11):630-41
pubmed: 16236519
J Control Release. 2018 Apr 10;275:117-128
pubmed: 29474960

Auteurs

Celine Bouclier (C)

Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France.

Matthieu Simon (M)

Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France.

Guillaume Laconde (G)

Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France.

Morgan Pellerano (M)

Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France.

Sebastien Diot (S)

Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France.

Sylvie Lantuejoul (S)

CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France.

Benoit Busser (B)

CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France.
Institut pour l'Avancée des Biosciences, INSERM U1209, CNRS UMR-5309, Université Grenoble Alpes, Grenoble, France.

Laetitia Vanwonterghem (L)

Institut pour l'Avancée des Biosciences, INSERM U1209, CNRS UMR-5309, Université Grenoble Alpes, Grenoble, France.

Julien Vollaire (J)

Institut pour l'Avancée des Biosciences, INSERM U1209, CNRS UMR-5309, Université Grenoble Alpes, Grenoble, France.

Véronique Josserand (V)

Institut pour l'Avancée des Biosciences, INSERM U1209, CNRS UMR-5309, Université Grenoble Alpes, Grenoble, France.

Baptiste Legrand (B)

Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France.

Jean-Luc Coll (JL)

Institut pour l'Avancée des Biosciences, INSERM U1209, CNRS UMR-5309, Université Grenoble Alpes, Grenoble, France.

Muriel Amblard (M)

Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France.

Amandine Hurbin (A)

Institut pour l'Avancée des Biosciences, INSERM U1209, CNRS UMR-5309, Université Grenoble Alpes, Grenoble, France.

May C Morris (MC)

Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH